← Tango Therapeutics, Inc. (TNGX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tango Therapeutics, Inc. (TNGX)
Pharmaceutical Preparations · market cap $4.2B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
5
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Tango Therapeutics (TNGX) is a clinical-stage pharmaceutical company with a market cap of ~$4.5B and a fully Phase 2 pipeline spanning NSCLC, locally advanced solid tumors, and PDAC. The company carries ~$157.8M in cash, implying a runway of roughly 10-11 months, with multiple mid-stage readouts expected across 2027. Short interest stands at a notable 29% of float, reflecting significant market skepticism despite a sell-side consensus of strong buy.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-03-31 (est.)Phase 2 · TNG456imp 7/10
- 2027-06-15 (est.)Phase 2 · RMC-9805imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TNG260 | Phase 2 | Non Small Cell Lung Cancer |
| TNG462 | Phase 2 | Locally Advanced Solid Tumor |
| TNG456 | Phase 2 | Non Small Cell Lung Cancer |
| RMC-9805 | Phase 2 | PDAC |
| TNG908 | Phase 2 | Locally Advanced Solid Tumor |
Price & technical context
3-month
-17.0%
6-month
+15.2%
12-month
+191.1%
52-wk range
$6.91–$32.90
vs 50-day MA
-2.3%
vs 200-day MA
+17.1%
Realized vol
93.6%
Max drawdown
-89.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TNGX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.